Evidence Explorer · MS-N286 · Investigational oncolytic therapy · Appraised November 9, 2026
Newcastle disease virus is a real oncolytic-virus research platform, but it is not an established natural cancer cure. Older studies were small and weakly controlled; a modern engineered-virus combination produced responses in an early phase I trial but substantial grade 3–4 toxicity and no randomized efficacy evidence.
Evidence at a glance
- Populations: heterogeneous advanced solid tumors in phase I studies; older studies also tested virus-modified tumor vaccines.
- Interventions vary fundamentally by strain, engineering, route, dose and whether combined with immunotherapy.
- Modern phase I result: 39 received MEDI5395; 36 also received durvalumab. Four partial responses occurred, while 27 participants (69.2%) had grade 3–4 treatment-emergent events.
- Evidence label: investigational early-phase evidence; no established survival benefit.
What was studied
NCI concluded that older clinical reports were inconclusive because of small samples, historical rather than concurrent controls, incomplete reporting and heterogeneous products.
In the 2024 MEDI5395 phase I study, all 39 participants experienced at least one treatment-emergent event. The dose-expansion phase was not initiated, and four partial responses in a single-arm study cannot separate virus effects from durvalumab or patient selection.
An earlier PV701 phase I study enrolled 79 people and primarily established dose and tolerability. Flu-like symptoms were common, and response observations warranted research rather than routine use.
What this evidence cannot establish
“Newcastle disease virus” is not one interchangeable product. Veterinary virus, older MTH-68/N or PV701 preparations, cell vaccines and engineered clinical-grade vectors cannot be pooled as a single therapy or self-administered.
Safety and practical context
Reported effects include fever, chills, fatigue, nausea, infusion reactions, immune effects and tumor-site symptoms. Modern combination therapy produced frequent severe events and requires biosafety oversight.
Do not use veterinary vaccines or unregulated viral products. Investigational oncolytic viruses require clinical-grade manufacturing, containment, shedding precautions and a monitored trial.
Questions for the care team
- Which exact strain, engineered construct and clinical-grade manufacturer are involved?
- Is the study registered and overseen by an oncology center and biosafety program?
- What response, shedding and severe-toxicity data exist for this exact product and combination?
Sources and identifiers
- NCI Newcastle Disease Virus PDQ
- MEDI5395 plus durvalumab phase I study — PMID 39551600
- PV701 phase I study — PMID 11980996
- PV701 two-step desensitization phase I study — PMID 16638865
Funding and conflicts: The MEDI5395 program was developed and sponsored by AstraZeneca; several authors were employees or reported industry relationships. Older programs had product-developer involvement.
Source access and dates: Original reports, registry records and official safety sources available through the links above were checked November 9, 2026. Last literature search November 9, 2026.
Educational evidence summary, not individualized medical advice. Investigational or repurposed products should not replace established cancer treatment. Symptom, biomarker, laboratory or animal findings do not establish tumor control, recurrence prevention or longer survival.
